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patients had a complete response and four had a partial
response, giving an overall response rate of 75%. Three
patients are alive from 6 to 21 months after HSCT. One
patient is well and two have chronic GVHD. Two patients
showed no response at all.
Thus, FMCs may be successfully used for immune
modulation and tissue repair.Table 1
ST2 concentrations at D14 predict GVHD development by D100 and predict
D180 NRM
UM FIC (n ¼ 414) UM RIC
(n ¼ 184)
DFCI
(n ¼ 75)
Hazard
Ratio
(HR)
P-
value
HR P-
value
HR P-
value
Age (55 and
Over vs.
Under 55)
1.5 0.01 0.8 0.4 0.1 0.02
Disease Status
(High vs.
Low risk)
1.0 0.99 1.8 0.02 n/a
Donor 1.9 <0.001 0.9 0.7 n/a59
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Fungal infection is a serious complication after allogeneic
hematopoietic stem cell transplantation but its impacts on
graft-versus host disease (aGVHD) remains to be elucidated.
a-mannan, one of the main components of fungal cell wall,
induces Th17 responses, leading to the elimination of fungi.
We therefore hypothesized that fungal infection could
modulate GVHD by inducing Th17 responses. Lethally irra-
diated B6D2F1 (H-2b/d) mice were injected with 4 x 106 BM
and 4 x 106 T cells from MHC-mismatched B6 (H-2b) donors
on day 0. Mice were intraperitoneally injected with 20mg of
a-mannan or diluent on day 1. GVHD was severe in mannan-
treated allogeneic mice, with 16.7% survival by day30,
whereas 83.3% of allogeneic controls survived this period
(Table). Histopathologic examination showed signiﬁcantly
exacerbation of GVHD pathology, especially in the lung, of
mannan-treated animals than in controls (Table).
A ﬂowcytometric analysis of the spleen and thymus after
BMT showed that administration of mannan did not alter
donor cell engraftment.
We then evaluated the roles of Th17 in aGVHD of
mannan-treated allogeneic models using IL-17-deﬁcient
mice as donors. Infusion of IL-17-/- T cells signiﬁcantly
improved GVHD clinical scores (3.5 0.4 vs 5.50.3 at day14,
P<.05), survival (62.5% vs 12.5% at day 30, P < .05) and
pulmonary GVHD pathology scores (1.00.5 vs 7.01.0 at
day21, P < .05) compared with those of mannan-treated
controls.
These results suggest that mannan can exacerbate acute
GVHD, mainly on pulmonary lesions.Th17 contribute to the
development of acute pulmonary GVHD in this model, and
that targeting Th17 may therefore represent a promising
therapeutic strategy for treating acute pulmonary GVHD.Table
Group Clinical
GVHD
scores
on
day+14
Survivals
on
day+30
(%)
Pathology Scores
Lung Liver Intestine
TCD Diluent 1.10.8 100 0 0.30.4 0.70.4
TCD a-mannan 1.20.5 100 0 0.70.8 0.50.5
+T Diluent 3.60.7 83.3 1.50.7 2.5 1.2 2.0 0.8
+T a-mannan 5.70.5y 16.7* 7.01.0y 4.0 1.8 2.5 0.8
TCD: T cell-depleted BMT, +T: T cell-repleted BMT.
Data are expressed as mean  SD.
* P < 0.01 vs control.
y P<0.05 vs control.60
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Acute GVHD is the primary limitation of allogeneic HSCT.
We have previously reported that plasma concentrations of
suppressor of tumorigenicity 2 (ST2) at the onset of GVHD
therapy predicted response at day (D) 28 and non-relapse
mortality (NRM) at D180 after therapy initiation. We
hypothesized that ST2measured early in HSCTwould predict
GVHD occurrence by D100 and D180 NRM after HSCT.
We measured ST2 in plasma taken at D0, D14 and D21
after HSCT in a pilot set. ST2 concentrations at D14weremost
different between patients who developed GVHD and those
without GVHD, and were twice higher in patients receiving
full intensity conditioning (FIC) compared to those receiving
reduced intensity conditioning (RIC). We then measured ST2
concentrations at D14 in two independent sets: 1) 598
patients from the University of Michigan (UM), 69% receiving
FIC (15% receiving TBI) and 31% receiving RIC HSCT, 2) 75
patients receiving unrelated, FIC (92% receiving TBI) HSCT
from the Dana Farber Cancer Institute (DFCI). UM patients
who developed GVHD were older and more likely to receive
mismatched or unrelated donor HSCT. Median day of GVHD
onset was D35 in FIC and D42 in RIC (p¼0.08). DFCI patients
who received sirolimus as GVHD prophylaxis were over-(Unrelated
vs. Related)
HLA match
(Mismatched
vs. Matched)
2.1 <0.001 1.0 0.9 2.7 0.09
ST2 Concentration
(High vs.
Low)*,y
1.5 0.004 1.3 0.3 2.0 0.08
Age 3.1 <0.001 0.7 0.4 0.7 0.5
Disease Status 1.1 0.6 2.7 0.02 n/a
Donor 1.5 0.1 1.1 0.8 n/a
HLA match 1.7 0.06 0.5 0.3 1.9 0.2
ST2 Concentration 2.8 <0.001 4.8 0.005 2.6 0.04
* Effect of ST2 calculated with regression models adjusting for age,
disease status, donor, and HLA match.
y High deﬁned as ST2 concentration >600 pg/mL for UM FIC, >300 pg/mL
for UM RIC, >1660 pg/mL for DFCI.
